Friday, November 13, 2026

GBP/EUR Went Down By Over 1% In The Last 10 Sessions

Automated market report from our archive (2020–2024), published before source-traceability. How we work

GBP/EUR Went Down By Over 1% In The Last 10 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.18% for the last 10 sessions. At 15:11 EST on Sunday, 23 July, GBP/EUR (GBPEUR) is $1.16.

GBP/EUR's yearly highs and lows, it's 6.816% up from its 52-week low and 3.662% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.24%, a negative 0.03%, and a positive 0.26%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.28% (last week), 0.29% (last month), and 0.26% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • Eur/usd holds steady around 1.1135-40 area, just above one-week low set on Thursday. According to FXStreet on Friday, 21 July, "The US Dollar (USD) is seen consolidating the overngith strong gains led by the upbeat US Jobless Claims data and turning out to be a key factor acting as a tailwind for the EUR/USD pair. ", "Nevertheless, the EUR/USD pair remains on track to register weekly losses and remains at the mercy of the USD price dynamics in the absence of any relevant market moving economic relesaes, either from the Euro Zone or the US."
  • Eur/usd price analysis: euro flirts with support-turned-resistance near 1.1150 as ecb, fed verdicts loom. According to FXStreet on Friday, 21 July, "Even so, the 10-day Exponential Moving Average (EMA) restricts the immediate downside of the EUR/USD pair near the 1.1130 level, especially amid the firmer RSI (14) line, not overbought.", "Following that, multiple levels near 1.1200 and 1.1230 can prod the EUR/USD bulls before directing it to the 1.1280 resistance area comprising technical swings marked during late 2021 and early 2022."
  • Eur/usd could drift down to support at 1.1100/1115 – ING. According to FXStreet on Friday, 21 July, "Back to today, EUR/USD could drift down to support at 1.1100/1115 but that may well be the lower end of the range heading into next week's central bank meetings.", "Both of these variables have to change if the EUR/USD is to embark on a big cyclical rally."
  • Eur/usd could dip back towards the 1.1050 area on the fed event risk – ING. According to FXStreet on Friday, 21 July, "Clearly, fireworks are not expected, but EUR/USD could dip back towards the 1.1050 area on the Fed event risk."
  • Eur/usd: weekly forecast 23rd July - 29th July - 23 July 2023. According to DailyForex on Sunday, 23 July, "However, after reaching this apex long-term high early last week, the EUR/USD also mirrored broad Forex conditions and started to produce a rather fast sell-off which escalated as the weekend approached. ", "The fast selling of the EUR/USD mirrored the broad Forex market, but the currency pair remains rather healthy and within the higher elements of its mid and long-term price ranges. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com